Discover more
than you think
Developing innovative cancer treatments tackling GPCR mediated-immunosuppression
-
Discover more
A2aR/A2bR antagonist for immuno-oncology
Immuno-oncology
programs
We are advancing multiple first-in-class and best-in class programs to tackle GPCR-mediated immunosuppression in immune-oncology
Immuno-oncology pipeline
| Name | Discovery | Candidate | Preclinical | Clinical | Partner |
|---|---|---|---|---|---|
| A2aR/A2bR antagonist |
Preclinical
|
||||
| EP4R antagonist (DT-9081) |
Preclinical
|
||||
| anti-CCR8 antibody |
Discovery
|
||||
| Undisclosed GPCR targets |
Discovery
|
||||
Our unique
positioning
We build a high value pipeline focused on GPCRs to rearm immune system against tumors.
